Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 2Osteosarcoma 1Neoplasms 1Neoplasm Metastasis 1Keratoacanthoma familial 1Dermoid Cyst 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Camurati-Engelmann Syndrome 1

Interventions

Cisplatin 3pembrolizumab 2bintrafusp alfa protein, human 2Gemcitabine 2vactosertib 1enzalutamide 1Trabedersen 1Temozolomide 1Sorafenib 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Paclitaxel 1Lomustine 1LY3300054 1LY-2157299 1Drug Delivery Systems 1Carboplatin 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Camurati-Engelmann Syndrome × vactosertib × Clear all
NCT02160106 2019-05-09

First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors

MedPacto, Inc.

Phase 1 Completed
35 enrolled

Keratoacanthoma familial, Camurati-Engelmann Syndrome, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡